The New York Times has been running a highly informative series on the progress of immunotherapy in treating cancer.
I don’t know about you, but I’m always tempted to ignore articles about cancer. If I ignore it, perhaps it will ignore me.
But this is not a common sense approach. I’ve known too many seniors, close friends and relatives, who have waged epic struggles against the disease. I could well be affected too, as might loved ones. Common sense suggests that I should be as well informed as possible.
Anyway, the news about cancer is a lot better today, and a lot easier to read about, than it was just a short time ago thanks to the gains in immunotherapy. That’s why the recent New York Times series on the subject is so helpful.
The times laid out the fundamentals on Sunday with What is Immunotherapy? The Basics on These Cancer Treatments. On Monday, the paper followed up with detailed personal stories, focusing on checkpoint inhibitors — drugs that empower the body’s immune system. On Tuesday, the Times turned to cell therapy, the other major line of approach to immunotherapy.
Immunotherapy doesn’t always achieve remission, and remissions may not last forever, but remarkable progress has been made. That’s worth reading about.